Can AI Outperform Doctors at Detecting Cervical Cancer?

Article

A new computer algorithm was able to accurately analyze digital images of cervical screenings and identify precancerous changes that required further medical follow-up.

A computer algorithm was able to accurately analyze digital images of cervical screenings and identify precancerous changes that required further medical follow-up, a new study showed. The new approach, called automated visual evaluation, has the potential to change point-of-care cervical screening.

“Our findings show that a deep learning algorithm can use images collected during routine cervical cancer screening to identify precancerous changes that, if left untreated, may develop into cancer,” Mark Schiffman, MD, MPH, of the National Cancer Institute's Division of Cancer Epidemiology and Genetics, and senior author of the study said in a press release. “In fact, the computer analysis of the images was better at identifying precancer than a human expert reviewer of Pap tests under the microscope (cytology).”

According to the release, the artificial intelligence (AI) method is easy to perform. Health workers can use a cell phone or similar camera device for cervical screening and treatment during a single visit. In addition, this approach can be performed with minimal training, making it ideal for countries with limited health care resources, where cervical cancer is a leading cause of illness and death among women.

To create the algorithm, Schiffman and colleagues used information from a population-based longitudinal cohort study of 9,406 women aged 18–94 years in Guanacaste, Costa Rica. During a 7-year period, women underwent multiple cervical screening methods and histopathologic confirmation of precancers.

A tumor registry was used to link identified cervical cancers up to 18 years out from the study. More than 600,000 archived, digital cervical images taken at screening were used for training and validation of the deep learning-based algorithm.

The automated visual evaluation method performed better than all standard screening methods at identifying cases of cervical cancer diagnosed during the Costa Rica study. The AI method had greater accuracy (area under the curve [AUC] =0.91) than human expert review (AUC = 0.69) or conventional cytology (AUC = 0.71).

Looking at a single screening round of women aged 25–49, the automated visual evaluation identified 55.7% of 228 precancers and referred 11% for management.

Maurie Markman, MD, president of Medicine & Science at Cancer Treatment Centers of America, who was not involved in the research, told Cancer Network that this was a provocative report that utilizes modern technology to help deal with a critical cancer screening issue in low-resource settings.

“While additional work is required to optimize this deep learning algorithm employing an automated evaluation of images of the cervix the potential exists that this strategy could substantially favorably impact cervix cancer-associated morbidity and mortality in these clinical settings,” he said.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content